Dr. Agarwal's Health Care Limited IPO
₹382 - ₹402
35
N/A
| Open Date: | 29-Jan-2025 |
| Close Date: | 31-Jan-2025 |
| Allotment Date: | 03-Feb-2025 |
| Listing Date: | 05-Feb-2025 |
| Listing Price: | N/A |
| Face Value: | ₹₹1 Per Equity Share Per Equity Share |
| Issue Price: | ₹₹382-402 per equity share Per Equity Share |
| Issue Size: | Total ₹3,027.76 Cr : #Fresh Issue : 74,62,686 shares(aggregating up to ₹300.00 Cr) + #OFS : 6,78,42,284 shares of ₹1(aggregating up to ₹2,727.26 Cr) |
| Market Lot (Min Amount): | 35 Shares (₹14,070/-) |
| Earning Per Share(EPS) | ₹3.08/- |
| P/E Ratio | 130.44 |
| RoNW | 9.33% |
| Net Asset Value (NAV) - Post Issue: | ₹N/A/- |
| Total Assets | Total Revenue | Profit After Tax | |
|---|---|---|---|
| 31 Mar,2024 | 2,752.82 | 1,376.45 | 95.05 |
| 31 Mar,2023 | 1,825.17 | 1,031.49 | 103.23 |
| 31 Mar,2022 | 1,026.13 | 713.78 | 43.16 |
| Pre Issue Share Holding | N/A |
| Post Issue Share Holding | N/A |
| 1. Dr. Amar Agarwal, |
| 2. Dr. Athiya Agarwal |
| 3. Dr Adil Agarwal |
| 4. Dr. Anosh Agarwal |
| 5. Dr Ashvin Agarwal |
| 6. Dr. Ashar Agarwal |
| 7. Dr. Amar Agarwal Family Trust |
| 8. Dr Adil Agarwal Family Trust |
| 9. Dr. Anosh Agarwal Family Trust |
| 10. Dr Ashvin Agarwal Family Trust |
| 11. Dr. Ashar Agarwal Family Trust |
| 12. Dr Agarwal’s Eye Institute |
| 13. Dr Agarwal's Eye Institute Private Limited |
- Repayment/prepayment, in part or full, of certain of the borrowings
- General corporate purposes and unidentified inorganic acquisition.
Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.
As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.
The Services provided by the company are:-
Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;
Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).
Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.
As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).
As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.
Competitive Strength
- Largest eye care services provider in India with a trusted brand
- End-to-end, comprehensive eye care services offering
- Scalable, asset-light, hub-and-spoke operating model
- Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations.
- Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
- Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.